The Duke University CFAR Social and Behavioral Sciences (SBS) Core (Core G) is the primary hub for university wide scientific consultation on the design and conduct of social and behavioral studies related to HIV infection. In line with the overall mission for a CFAR, this Core provides """"""""value-added"""""""" services to enhance and further develop the conduct of social and behavioral science HIV/AIDS research at Duke. The Core has four aims: 1) Enhance the quality and quantity of social and behavioral HIV/AIDS research at Duke, through the provision of scientific consultations throughout the grant development and research process;2) Build the individual and collective capacity of Duke SBS researchers, by attracting and supporting new investigators, providing mentorship and training, and facilitating networking among investigators at Duke and between Duke and other CFARs;3) Enhance the reach and impact of Duke SBS studies by assisting researchers in the dissemination of their findings to the study community and the larger scientific community, and by assisting researchers with the community engagement process in order to prioritize research that reflects community need;and 4) Enhance the conduct of SBS research in the Duke Infectious Diseases Clinic by building a clinic database of psychosocial variables, which can be used to support new grant applications and to recruit patients into SBS and clinical studies. Building on the strengths and expertise of Duke investigators, the Core is helping to promote research innovation across four main areas: social determinants of HIV infection;substance abuse and mental health;intervention trials;and biobehavioral studies.
The SBS Core is enhancing innovative social-behavioral research on HIV by supporting investigators with scientific consultation throughout the grant cycle by pro-actively offering mentorship and networking. The Core is building the individual and collective capacity for cross-disciplinary research and the Core's efforts in the Duke ID clinic are creating new opportunities for SBS research in the clinical setting.
|Ramadhani, Habib O; Muiruri, Charles; Maro, Venance P et al. (2017) Patient-Initiated Repackaging of Antiretroviral Therapy, Viral Suppression and Drug Resistance. AIDS Behav :|
|Han, Qifeng; Williams, Wilton B; Saunders, Kevin O et al. (2017) HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques. J Virol 91:|
|Margolis, David M; Koup, Richard A; Ferrari, Guido (2017) HIV antibodies for treatment of HIV infection. Immunol Rev 275:313-323|
|Pollara, Justin; Easterhoff, David; Fouda, Genevieve G (2017) Lessons learned from human HIV vaccine trials. Curr Opin HIV AIDS 12:216-221|
|Wang, Kening; Tomaras, Georgia D; Jegaskanda, Sinthujan et al. (2017) Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice J Virol 91:|
|Price, Alexander M; Dai, Joanne; Bazot, Quentin et al. (2017) Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infection. Elife 6:|
|Martinez, David R; Vandergrift, Nathan; Douglas, Ayooluwa O et al. (2017) Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk. J Virol 91:|
|Marks, Florian; von Kalckreuth, Vera; Aaby, Peter et al. (2017) Incidence of invasive salmonella disease in sub-Saharan Africa: a multicentre population-based surveillance study. Lancet Glob Health 5:e310-e323|
|Towe, Sheri L; Patel, Puja; Meade, Christina S (2017) The Acceptability and Potential Utility of Cognitive Training to Improve Working Memory in Persons Living With HIV: A Preliminary Randomized Trial. J Assoc Nurses AIDS Care 28:633-643|
|Kelly, Matthew S; Surette, Michael G; Smieja, Marek et al. (2017) The Nasopharyngeal Microbiota of Children With Respiratory Infections in Botswana. Pediatr Infect Dis J 36:e211-e218|
Showing the most recent 10 out of 468 publications